Trial Schema & Aims
* The carboplatin dose recommended for ICON7 is AUC6 (unless predetermined as being different by individual GCIG group)
**Bevacizumab can be omitted from the first cycle if cytotoxic chemotherapy must be started within 4 weeks of surgery.
Primary outcome measure:
Progression Free Survival (PFS)
Secondary outcome measures:
Overall Survival (OS) Response Rate and Duration of Response Biological Progression Free Interval (PFIBIO) Safety
Related ICON7 Substudies:
Quality of Life (QoL) Health Economics (HE) Translational (biomarker) Research